Table of Content

1. mRNA Vaccines as Next Generation Cancer Immunotherapy
1.1 mRNA Vaccines Overview
1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
1.3 mRNA Vaccines v/s Other Vaccines


2. Global mRNA Cancer Vaccines Market Overview
2.1 Current Market Landscape
2.2 Future Clinical & Commercialization Opportunities


3. Global mRNA Cancer Vaccines Market Trends by Country
3.1 US
3.2 China
3.3 Australia
3.4 Europe
3.5 Canada


4. Global mRNA Cancer Vaccines Market Collaborations, Deals & Investments


5. Global mRNA Cancer Vaccines Market Clinical Landscape by Indication
5.1 Breast Cancer
5.2 Brain Cancer
5.3 Melanoma
5.4 Colorectal Cancer
5.5 Head & Neck Cancers


6. Global mRNA Cancer Vaccines Clinical Pipeline Overview
6.1 By Company
6.2 By Country
6.3 By Patient Segment
6.4 By Phase
6.5 By Priority Status


7. Global mRNA Cancer Vaccines Clinical Pipeline By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III


8. Proprietary Technologies & Methodologies for RNA Cancer Vaccines Development
8.1 FixVac - BioNTech
8.2 iNeST – BioNTech
8.3 NanoReady - Samyang Holdings
8.4 CureVac Method - CureVac
8.5 mRNA platform - Moderna
8.6 NeoCura Ag - NeoCura


9. Competitive Landscape
9.1 Avstera Therapeutics
9.2 BioNTech
9.3 Combined Therapeutics
9.4 CureVac
9.5 EpiVax
9.6 Immorna
9.7 Immune Design
9.8 MDimune
9.9 Moderna Therapeutics
9.10 NeoCura
9.11 Orna Therapeutics
9.12 pHion Therapeutics
9.13 Regen BioPharma
9.14 RNAimmune
9.15 TransCode Therapeutics



List of Figures

Figure 5-1: KEYNOTE-603 Phase I Study – Initiation & Completion Years
Figure 5-2: GO39733 Phase I Study – Initiation & Completion Years
Figure 5-3: ATTAC-II Phase II Study – Initiation & Completion Years
Figure 5-4: CV-GBLM-001 Phase I Study – Initiation & Completion Years
Figure 5-5: GO39733 Phase II Study – Initiation & Completion Years
Figure 5-6: BNT111-01 Phase II Study – Initiation & Completion Years
Figure 5-7: BNT122-01 Phase II Study – Initiation & Completion Years
Figure 5-8: AHEAD-MERIT Phase II Study – Initiation & Completion Years
Figure 5-9: KEYNOTE-603 Phase II Study – Initiation & Completion Years

Figure 6-1: Global – mRNA Cancer Vaccines Clinical Pipeline by Company
(Numbers), 2023
Figure 6-2: Global – mRNA Cancer Vaccines Clinical Pipeline by Country (Numbers) 2023
Figure 6-3: Global – mRNA Cancer Vaccines Clinical Pipeline by Patient Segment
(Numbers), 2023
Figure 6-4: Global – mRNA Cancer Vaccines Clinical Pipeline by Phase (Numbers) 2023
Figure 6-5: Global – mRNA Cancer Vaccines Clinical Pipeline by Priority Status
(Numbers), 2023

Figure 8-1: BioNTech – uRNA products
Figure 8-2: BioNTech – iNeST technology
Figure 8-3: CureVac - CureVac Method for Generation of mRNA Therapeutics
Figure 8-4: Moderna - mRNA Technology
Figure 8-5: NeoCura – NeoCura Ag Platform
 

List of Tables

Table 1-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
Table 1-2: mRNA-Based Cancer Vaccines vs. Other Cancer Vaccines

Table 2-1: Recent Designations Granted to Investigational mRNA Cancer Vaccines

Table 5-1: Breast Cancer mRNA Vaccines in Clinical Trials
Table 5-2: Brain Cancer mRNA Vaccines in Clinical Trials
Table 5-3: Melanoma mRNA Vaccines in Clinical Trials
Table 5-4: Colorectal Cancer mRNA Vaccines in Clinical Trials
Table 5-5: Head & Neck Cancer mRNA Vaccines in Clinical Trials